enVVeno Medical Reports Fourth Quarter and Year-End 2024 Financial Results and Progress Towards VenoValve FDA Approval Expected in 2H25

Stock Information for Volato Group Inc. Class A

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Volato Group Inc. Class A

enVVeno Medical (NASDAQ:NVNO) to Participate in a Live Virtual Investor CEO Connect Segment
enVVeno Receives Unfavorable Appeal Decision from the FDA for the VenoValve
enVVeno Medical Reports Third Quarter 2025 Financial Results and Provides Corporate Update
enVVeno Medical (NASDAQ:NVNO) Participates in Virtual Investor "What This Means" Segment
enVVeno Medical Updates Regulatory Status of VenoValve(R)
enVVeno Receives Not-Approvable Letter from the FDA for the VenoValve(R)
enVVeno Medical to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech
Health Economic Study Shows That enVVeno Medical's VenoValve(R) Would be a Cost-Effective Treatment Option for Patients with Severe Chronic Venous Insufficiency

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.